| TA112 |
Breast cancer (early) - hormonal treatments (TA112) |
|
-
-
early and locally advanced breast cancer
Fast, easy summary view of NICE guidance on 'early and locally advanced breast cancer'
-
-
-
Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Anastrozole, exemestane and letrozole are recommended as possible treatments for women who have a type of breast cancer called early oestrogen-receptor-positive breast cancer and have been through the menopause. Anastrozole, exemestane or letrozole may be given as an 'extra' treatment (called an adjuvant treatment), after the woman has had an operation to remove the cancer, to help to stop the cancer coming back.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: early and locally advanced breast cancer
How this guidance was produced
Background information
This page was last updated: 26 October 2011
-
-
Guidance formats
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
